Mechanisms inducing low bone density in duchenne muscular dystrophy in mice and humans

Abstract

Patients affected by Duchenne muscular dystrophy (DMD) and dystrophic MDX mice were investigated in this study for their bone phenotype and systemic regulators of bone turnover. Micro–computed tomographic (µCT) and histomorphometric analyses showed reduced bone mass and higher osteoclast and bone resorption parameters in MDX mice compared with wild-type mice, whereas osteoblast parameters and mineral apposition rate were lower. In a panel of circulating pro-osteoclastogenic cytokines evaluated in the MDX sera, interleukin 6 (IL-6) was increased compared with wild-type mice. Likewise, DMD patients showed low bone mineral density (BMD) Z-scores and high bone-resorption marker and serum IL-6. Human primary osteoblasts from healthy donors incubated with 10% sera from DMD patients showed decreased nodule mineralization. Many osteogenic genes were downregulated in these cultures, including osterix and osteocalcin, by a mechanism blunted by an IL-6-neutralizing antibody. In contrast, the mRNAs of osteoclastogenic cytokines IL6, IL11, inhibin-βA, and TGFβ2 were increased, although only IL-6 was found to be high in the circulation. Consistently, enhancement of osteoclastogenesis was noted in cultures of circulating mononuclear precursors from DMD patients or from healthy donors cultured in the presence of DMD sera or IL-6. Circulating IL-6 also played a dominant role in osteoclast formation because ex vivo wild-type calvarial bones cultured with 10% sera of MDX mice showed increase osteoclast and bone-resorption parameters that were dampen by treatment with an IL-6 antibody. These results point to IL-6 as an important mediator of bone loss in DMD and suggest that targeted anti-IL-6 therapy may have a positive impact on the bone phenotype in these patients. © 2011 American Society for Bone and Mineral Research

Shown for reading. Its publisher allows quoting it, not republishing it.

References 57

1. 1.

   Kunkel LM, Beggs AH, Hoffman EP. Molecular genetics of Duchenne and Becker muscular dystrophy: emphasis on improved diagnosis. Clin Chem. 1989;35:B21-B24.

   Not in our library

2. 2.

   Emery AE. Population frequencies of inherited neuromuscular diseases: a world survey. Neuromusc Disord. 1991;1:19-29.

   Not in our library10.1016/0960-8966(91)90039-u

3. 3.

   Suresh S, Wales P, Dakin C, Harris MA, Cooper DG. Sleep-related breathing disorder in Duchenne muscular dystrophy: disease spectrum in the paediatric population. J Paediatr Child Health. 2005;41:500-503.

   Not in our library10.1111/j.1440-1754.2005.00691.x

4. 4.

   Ervasti JM, Campbell KP. A role for distrohyn-glycoprotein complex as an transmembrane linker between laminin and actin. J Cell Biol. 1993;122:809-823.

   Not in our library10.1083/jcb.122.4.809

5. 5.

   Campbell KP. Three muscular dystrophies: loss of cytoskeleton-extracellular matrix linkage. Cell. 1995;80:675-679.

   Not in our library10.1016/0092-8674(95)90344-5

6. 6.

   Petrof BJ. The molecular basis of activity-induced muscle injury in Duchenne muscular distrophy. Mol Cell Biochem. 1998;179:111-123.

   Not in our library10.1023/a:1006812004945

7. 7.

   Wehling M, Spencer MJ, Tidball JG. A nitric oxide synthase transgene ameliorates muscular dystrophy in mdx mice. J Cell Biol. 2001;155:123-131.

   Not in our library10.1083/jcb.200105110

8. 8.

   Wakayama Y, Jimi T, Inoue M, et al. Reduced aquaporin 4 expression in the muscle plasma membrane of patients with Duchenne muscular dystrophy. Arch Neurol. 2002;59:431-437.

   Not in our library10.1001/archneur.59.3.431

9. 9.

   Kumar A, Khandelwal N, Malya R, Reid MB, Boriek AM. Loss of dystrophin causes aberrant mechanotransduction in skeletal muscle fibers. FASEB J. 2004;18:102-113.

   Not in our library10.1096/fj.03-0453com

10. 10.

    Deconinck N, Dan B. Pathophysiology of Duchenne muscular distrophy: Current hypotheses. Pediatr Neurol. 2007;36:1-7.

    Not in our library10.1016/j.pediatrneurol.2006.09.016

11. 11.

    McDouall RM, Dunn MJ, Dubowitz V. Nature of the mononuclear infiltrate and the mechanism of muscle damage in juvenile dermatomyositis and Duchenne muscular dystrophy. J Neurol Sci. 1990;99:199-217.

    Not in our library10.1016/0022-510x(90)90156-h

12. 12.

    Porter JD, Khanna S, Kaminski HJ, et al. A chronic inflammatory response dominates skeletal muscle molecular signature in dystrophin−deficient mice. Hum Mol Genet. 2002;11:263-272.

    Not in our library10.1093/hmg/11.3.263

13. 13.

    Chen YW, Zhao P, Borup R, Hoffman EP. Expression profiling in the muscular dystrophies: identification of novel aspects of molecular pathophysiology. J Cell Biol. 2000;151:1321-1336.

    Not in our library10.1083/jcb.151.6.1321

14. 14.

    Pandya S, Guntrum D, Moxley RT. Long term daily prednisone therapy delays decline in pulmonary function and improves survival in patients with duchenne distrophy. Neurom Disord. 2005;15:687.

    Not in our library

15. 15.

    Wagner KM, Lechtzin N, Judge DP. Current treatment of adult Duchenne muscular distrophy. Biochim Biophys Acta. 2007;1772:229-237.

    Not in our library10.1016/j.bbadis.2006.06.009

16. 16.

    Olney RC. Mechanisms of impaired growth: effect of steroids on bone and cartilage. Horm Res. 2009;72(Suppl 1):30-35.

    Not in our library10.1159/000229761

17. 17.

    Weldon D. The effects of corticosteroids on bone growth and bone density. Ann Allergy Asthma Immunol. 2009;103:3-11.

    Not in our library10.1016/s1081-1206(10)60135-4

18. 18.

    Larson C. Henderson RC Bone mineral density and fractures in boys with Duchenne muscular Dystrophy. J Pediatr Orthop. 2000;20:71-78.

    Not in our library

19. 19.

    Bothweel JE, Gordon KE, Dooley JM, Mac Sween J, Cummunigs EA, Salisbury S. Vertebral fractures in boys with Duchenne muscular dystrophy. Clin Pediatr. 2003;42:353-356.

    Not in our library10.1177/000992280304200408

20. 20.

    Bianchi ML, Mazzanti A, Galbiati E, et al. Bone mineral density and bone metabolism in Duchenne muscular dystrophy. Osteoporos Int. 2003;14:761-767.

    Not in our library10.1007/s00198-003-1443-y

21. 21.

    Söderpalm AC, Magnusson P, Ahlander AC, et al. Low bone mineral density and decreased bone turnover in Duchenne muscular dystrophy. Neuromuscul Disord. 2007;17:919-928.

    Not in our library10.1016/j.nmd.2007.05.008

22. 22.

    Bulfield G, Siller WG, Wight PA, Moore KJ. X chromosome-linked muscular dystrophy (mdx) in the mouse. Proc Natl Acad Sci U S A. 1984;81:1189-1192.

    Not in our library10.1073/pnas.81.4.1189

23. 23.

    De Benedetti F, Rucci N, Del Fattore A, et al. Impaired skeletal development in IL−6 transgenic mice. A model for the impact of chronic inflammation on the growing skeletal system. Arthritis Rheum. 2006;54:3551-3563.

    Not in our library10.1002/art.22175

24. 24.

    Rucci N, Rufo A, Alamanou M, et al. The glycosaminoglycan-binding domain of PRELP acts as a cell type-specific NF-kappaB inhibitor that impairs osteoclastogenesis. J Cell Biol. 2009;187:669-683.

    Not in our library10.1083/jcb.200906014

25. 25.

    Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, et al. Bone histomorphometry: standardization of nomenclature, symbols, and units: report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 1987;2:595-610.

    Not in our library10.1002/jbmr.5650020617

26. 26.

    Carter DR, Bouxsein ML, Marcus R. New approaches for interpreting projected bone densitometry data. J Bone Miner Res. 1992;7:137-135.

    Not in our library10.1002/jbmr.5650070204

27. 27.

    Kröger H, Kotaniemi A, Vainio P, Alhava E. Bone densitometry of spine and femur in children by dual-energy X-ray absorptiometry. J Bone Miner Res. 1992;17:75-85.

    Not in our library10.1016/0169-6009(92)90712-m

28. 28.

    Marzia M, Sims NA, Voit S, et al. Decreased c-Src expression enhances osteoblast differentiation and bone formation. J Cell Biol. 2000;151:311-320.

    Not in our library10.1083/jcb.151.2.311

29. 29.

    Taranta A, Fortunati D, Longo M, et al. Imbalance of Osteoclastogenesis-Regulating Factors in Patients With Celiac Disease. J Bone Miner Res. 2004;19:1112-1121.

    Not in our library10.1359/jbmr.040319

30. 30.

    Tsangari H, Findlay DM, Zannettino ACW, Pan B, Kuliwaba JS, Fazzalari NL. Evidence for reduced bone formation surface relative to bone resorption surface in female femoral fragility fracture patients. Bone. 2006;39:1226-1235.

    Not in our library10.1016/j.bone.2006.06.019

31. 31.

    Nakagaki WR, Bertran CA, Matsumura CY, Santo-Neto H, Camilli JA. Mechanical, biochemical and morphometric alterations in the femur of mdx mice. Bone. 2010.

    Not in our library10.1016/j.bone.2010.09.011

32. 32.

    Montgomery E, Pennington C, Isales C, Hamrick MW. Muscle-bone interactions in dystrophin-deficient and myostatin-deficient mice. Anat Rec A Discov Mol Cell Evol Biol. 2005;286:814-822.

    Not in our library10.1002/ar.a.20224

33. 33.

    Spencer MJ, Tidball JG. Do immune cells promote the pathology of dystrophin−deficient myopathies? Neuromuscul Disord. 2001;11:556-564.

    Not in our library10.1016/s0960-8966(01)00198-5

34. 34.

    McDonald DG, Kinali M, Gallagher AC, et al. Fracture prevalence in Duchenne muscular dystrophy. Dev Med Child Neurol. 2002;44:695-698.

    Not in our library10.1017/s0012162201002778

35. 35.

    Raisz LG. Physiology and pathophysiology of bone remodeling. Clin Chem. 1999;45:1353-1358.

    Not in our library

36. 36.

    Goldring SR. Bone loss in chronic inflammatory conditions. J Musculoskelet Neuronal Interact. 2003;3:287-289.

    Not in our library

37. 37.

    Jacobs SC, Bootsma AL, Willems PW, Bär PR, Wokke JH. Prednisone can protect against exercise-induced muscle damage. J Neurol. 1996;243:410-416.

    Not in our library10.1007/bf00869001

38. 38.

    Goldring K, Jones GE, Thiagarajah R, Watt DJ. The effect of galectin-1 on the differentiation of fibroblasts and myoblasts in vitro. J Cell Sci. 2002;115:355-366.

    Not in our library10.1242/jcs.115.2.355

39. 39.

    Febbraio MA, Pedersen BK. Muscle-derived interleukin-6: mechanisms for activation and possible biological roles. FASEB J. 2002;16:1335-1347.

    Not in our library10.1096/fj.01-0876rev

40. 40.

    Fischer CP. Interleukin-6 in acute exercise and training: what is the biological relevance? Exerc Immunol Rev. 2006;12:6-33.

    Not in our library

41. 41.

    Kurek JB, Nouri S, Kannourakis G, Murphy M, Austin L. Leukemia inhibitory factor and interleukin-6 are produced by diseased and regenerating skeletal muscle. Muscle Nerve. 1996;19:1291-1301.

    Not in our library10.1002/(sici)1097-4598(199610)19:10<1291::aid-mus6>3.0.co;2-9

42. 42.

    Pfeilshifter J, Koditz R, Pfohl M, Schatz H. Changes in proinflammatory cytokine activity after menopause. Endocr Rev. 2002;23:90-119.

    Not in our library10.1210/edrv.23.1.0456

43. 43.

    Rusiñska A, ChlebnaSokó3 D. Evaluation of IL−1 and IL−6 in the etiopathogenesis ofidiopathic osteoporosis and osteopenia in children. Arch Immunol Therap Exp. 2005;53:257-265.

    Not in our library

44. 44.

    Roodman GD, Kurihara N, Ohsaki Y, et al. Interleukin 6. A potential autocrine/paracrine factor in Paget's disease of bone. J Clin Invest. 1992;89:46-52.

    Not in our library10.1172/jci115584

45. 45.

    Bataille R, Klein B. Role of interleukin-6 in multiple myeloma. Ann Med Interne. (Paris). 1992;143:77-79.

    Not in our library

46. 46.

    Wierzbowska A, Urbańska-Ryś H, Robak T. Circulating IL-6-type cytokines and sIL-6R in patients with multiple myeloma. Br J Haematol. 1999;105:412-419.

    Not in our library

47. 47.

    Devlin RD, Bone HG, Roodman GD. Interleukin-6: a potential mediator of the massive osteolysis in patients with Gorham-Stout disease. J Clin Endocrinol Metab. 1996;81:1893-1897.

    Not in our library10.1210/jcem.81.5.8626854

48. 48.

    Souza LS, Machado SH, Brenol CV, Brenol JC, Xavier RM. Growth velocity and interleukin 6 concentrations in juvenile idiopathic arthritis. J Rheumatol. 2008;35:2265-2271.

    Not in our library10.3899/jrheum.080199

49. 49.

    Luu HH, Song WX, Luo X, et al. Distinct Roles of Bone Morphogenetic Proteins in Osteogenic Differentiation of Mesenchymal Stem Cells. J Orthop Res. 2007;25:665-667.

    Not in our library10.1002/jor.20359

50. 50.

    Vukicevic S, Grgurevic L. BMP-6 and mesenchymal stem cell differentiation. Cytokine Growth Fac Rev. 2009;20:441-448.

    Not in our library10.1016/j.cytogfr.2009.10.020

51. 51.

    Karsenty G. Transcriptional control of skeletogenesis. Annu Rev Genomics Hum Genet. 2008;9:183-196.

    Not in our library10.1146/annurev.genom.9.081307.164437

52. 52.

    Hayashi O, Katsube Y, Hirose M, Ohgushi H, Ito H. Comparison of osteogenic ability of rat mesenchymal stem cells from bone marrow, periosteum, and adipose tissue. Calcif Tissue Int. 2008;82:238-247.

    Not in our library10.1007/s00223-008-9112-y

53. 53.

    Hu JC, Yamakoshi Y. Enamelin and autosomal-dominant amelogenesis imperfecta. Crit Rev Oral Biol Med. 2003;14:387-398.

    Not in our library10.1177/154411130301400602

54. 54.

    Girasole G, Passeri G, Jilka RL, Manolagas SC. Interleukin-11: a new cytokine critical for osteoclast development. J Clin Invest. 1994;93:1516-1524.

    Not in our library10.1172/jci117130

55. 55.

    Heymann D, Rousselle AV. gp130 Cytokine family and bone cells. Cytokine. 2000;12:1455-1468.

    Not in our library10.1006/cyto.2000.0747

56. 56.

    Pearsall RS, Canalis E, Cornwall-Brady M, et al. A soluble activin type IIA receptor induces bone formation and improves skeletal integrity. PNAS. 2008;105:7082-7087.

    Not in our library10.1073/pnas.0711263105

57. 57.

    De Benedetti F, Brunner H, et al. Tocilizumab in patients with systemic juvemile idiopathic arthritis: data from the palcebo controlled 12 week part of the phase 3 TENDER trial. Arthritis Rheum. 2010;62(Suppl 10):596.

    Not in our library

Cited by papers we hold 3

• P2X7 Purinoceptor Affects Ectopic Calcification of Dystrophic Muscles · 2022
  Not checked
• The use of umbilical cord‐derived mesenchymal stem cells in patients with muscular dystrophies: Results from compassionate use in real‐life settings · 2021
  Not checked
• The JAK/STAT Pathway in Skeletal Muscle Pathophysiology · 2019
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.